Information
-
Trademark
-
79368307
-
Serial Number
79368307
-
Registration Number
7416497
-
International Classifications
-
Filing Date
December 13, 2022
a year ago
-
Registration Date
June 18, 2024
4 months ago
-
Transaction Date
September 18, 2024
a month ago
-
Status Date
June 18, 2024
4 months ago
-
Published for Opposition Date
April 02, 2024
7 months ago
-
Location Date
June 17, 2024
4 months ago
-
Status Code
700
-
Current Location
FILE REPOSITORY (FRANCONIA)
Employee Name
BULLOFF, TOBY
-
Attorney Name
Timothy J. Kelly
-
Owners
Mark Drawing Code
4
Mark Identification
BIOSCEPTRE
Case File Statements
- GS0051: Biopharmaceutical and pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; veterinary preparations, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; veterinary preparations, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for veterinary purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for veterinary purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; cultures of microorganisms for medical and veterinary use; biological preparations for medical purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for medical purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; drugs for medical purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; drugs for medical purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; diagnostic preparations for medical purposes; enzymes for medical purposes; biochemical medicines for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; vaccines; bioengineering pharmaceutical solutions for use in expanding cells for therapeutic use to patients with blood cancers and other diseases; biopharmaceuticals, namely biopharmaceutical products for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; cells and biological preparations, namely, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue intended for medical and clinical use, including, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue; bioengineered cells for use in immunotherapies; diagnostic substances and diagnostic preparations for medical purposes; gene and cell therapy and prophylaxis products, namely, therapeutic pharmaceuticals for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; gene and cell therapy prophylaxis vector preparations for therapeutic purposes for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; pharmaceutical preparations and products, namely pharmaceutical preparations and products for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; pharmaceutical preparations in the nature of cell solutions to enable cell expansion for therapeutic purposes; reagents for ex vivo cell processing in particular media suitable for the expansion of cells for therapeutic purposes; cell products for therapeutic purposes, namely stem and progenitor cell, adult cell, immune cell, cell therapy and gene therapy products; cells for medical purposes
- GS0421: Analysis of biological samples; biopharmaceutical and pharmaceutical development and research and evaluation services in the field of cell based therapeutics and gene therapy for the treatment of disease, injuries and disorders; biotechnology laboratory services; medical and scientific laboratory services; scientific, medical and clinical research consultation services and scientific, medical and clinical research and development services, including in the field of hematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; medical and scientific research, namely, conducting pre-clinical and clinical trials for others; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations and substances for use in clinical trials; chemical analysis; industrial design; conducting technical project studies in the fields of medicine, biotechnology, therapeutics, pharmaceuticals, biopharmaceuticals, biotherapeutics, radiology, cardiology, oncology, epidemiology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gastroenterology, nephrology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, surgery, medical genetics, medical genomics, dermatology, immunology, and preventive medicine; research and development of new products for others; material testing; biological research; scientific laboratory services; scientific research; bacteriological research
Case File Event Statements
-
4/27/2023 - a year ago
1 - SN ASSIGNED FOR SECT 66A APPL FROM IB
Type: REPR
-
4/28/2023 - a year ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
5/2/2023 - a year ago
3 - APPLICATION FILING RECEIPT MAILED
Type: MAFR
-
9/18/2023 - a year ago
4 - ASSIGNED TO EXAMINER
Type: DOCK
-
9/18/2023 - a year ago
5 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
9/19/2023 - a year ago
6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Type: RFCR
-
9/30/2023 - a year ago
7 - REFUSAL PROCESSED BY MPU
Type: RFRR
-
9/30/2023 - a year ago
8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Type: RFCS
-
10/25/2023 - a year ago
9 - REFUSAL PROCESSED BY IB
Type: RFNT
-
2/8/2024 - 9 months ago
10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
2/8/2024 - 9 months ago
11 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
2/8/2024 - 9 months ago
12 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
2/28/2024 - 8 months ago
13 - EXAMINERS AMENDMENT -WRITTEN
Type: CNEA
-
2/28/2024 - 8 months ago
14 - EXAMINERS AMENDMENT E-MAILED
Type: GNEA
-
2/28/2024 - 8 months ago
15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Type: GNEN
-
2/28/2024 - 8 months ago
16 - EXAMINER'S AMENDMENT ENTERED
Type: XAEC
-
2/29/2024 - 8 months ago
17 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
3/13/2024 - 8 months ago
18 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
3/27/2024 - 7 months ago
20 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Type: OPNS
-
3/27/2024 - 7 months ago
19 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Type: OP2R
-
4/2/2024 - 7 months ago
21 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
4/2/2024 - 7 months ago
22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
4/16/2024 - 6 months ago
23 - NOTIFICATION PROCESSED BY IB
Type: GPNX
-
6/18/2024 - 4 months ago
24 - REGISTERED-PRINCIPAL REGISTER
Type: R.PR
-
6/18/2024 - 4 months ago
25 - NOTICE OF REGISTRATION CONFIRMATION EMAILED
Type: NRCC
-
9/18/2024 - a month ago
26 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Type: FICR
